Memory Disorders and Cognitive Neurology
428 East 72nd Street
Suite 500
New York, NY 10021
New and Existing Patients
Already a patient?
Login or sign-upto Connect Patient Portal to make an appointment
Locations and Appointments
New Patients
Insurances Accepted
Please contact the doctor's office to verify that your insurance is accepted.
AETNA
Aetna - NYP
Amida Care
Anthem Blue Cross Blue Shield
Anthem Blue Cross/Blue Shield
Anthem Blue Cross/Blue Shield Healthplus
CIGNA
EmblemHealth
Fidelis Care
Health Insurance Plan of NY (HIP)
Healthfirst
Healthspring
Local 1199
Molina Healthcare
Oxford Health Plans
Quality Health Management (QHM)
Rockefeller University/Luminare
United Healthcare
UnitedHealthcare
VNS Health
VNSNY CHOICE
WellCare
WorldWide Medical
About Michael Tai-ju Lin, M.D.
Board Certifications
- Neurology
Expertise
- Alzheimer's Disease
- Dementia
- Memory Impairment
Education
- Internship: University of California - San Francisco
- Medical School: University of California - San Francisco
- Residency: University of California - San Francisco
Languages
- English
Titles & Positions
- Associate Attending Neurologist
- Associate Professor of Neurology
- Associate Professor of Neuroscience
Hospital Affiliations
- NewYork-Presbyterian / Weill Cornell Medical Center
Education
- Medical School: University of California - San Francisco
- Residency: University of California - San Francisco
- Internship: University of California - San Francisco
Titles & Positions
- Associate Attending Neurologist
- Associate Professor of Neurology
- Associate Professor of Neuroscience
Board Certifications
- neurology
Languages Spoken
- english
Research
PET-guided Assessment of Amyloid Clearance and Outcomes in a Real-World Cohort of Patients with Alzheimer Disease undergoing Anti-Amyloid Therapy.
May 11, 2026Amyloid PET Z Score Quantification and Correlation with Visual Semiquantitative Grading.
May 04, 2026Cross-Platform Concordance of Quantitative Amyloid PET Z-Scores in a Real-World Clinical Cohort of Patients with Cognitive Impairment and Suspected Alzheimer Disease.
April 15, 2026